Le marché des tests de diagnostic du cancer du col de l'utérus devrait atteindre 7 165,92 millions de dollars US d'ici 2028, contre 5 141,25 millions de dollars US en 2021 ; il devrait croître à un TCAC de 4,9 % de 2021 à 2028.
Le cancer du col de l'utérus a un taux de mortalité important (près de 50 %), qui peut être réduit grâce à une détection et une prévention précoces. Les altérations précancéreuses offrent des possibilités de prévention et de traitement car la progression de la maladie est souvent retardée. Cependant, en raison d'un manque de sensibilisation ou d'accès aux services de diagnostic, de nombreux cas sont détectés à des stades ultérieurs de la progression de la maladie. Le virus du papillome humain (VPH) est une cause principale de cancer du col de l'utérus qui se transmet généralement par contact sexuel. Il existe plus de 100 souches de VPH, dont 13 sont à haut risque ou cancérigènes. Le gène actif - E6 ou E7 - détermine si une souche de VPH présente un risque élevé ou faible. E6 se lie à p53, provoquant une destruction protéolytique. E7, d'autre part, se lie au rétinoblastome; la liaison déplace les facteurs de transcription précédemment attachés, ce qui entraîne l'arrêt du cycle cellulaire et l'inhibition de la régulation de l'apoptose. Le test HPV détecte le virus du papillome humain dans les cellules cervicales. D'autres approches de dépistage employées dans les régions à faibles ressources des pays en développement sont les tests d'ADN du VPH et l'inspection visuelle. Le dépistage du col de l'utérus sur une base régulière aide à une détection précoce du cancer du col de l'utérus, réduisant ainsi le taux de mortalité dû à la maladie. Tous les trois ans, toutes les femmes âgées de 21 à 65 ans sont invitées à subir un test Pap, et les femmes âgées de 30 à 65 ans sont invitées à subir à la fois un test Pap et un test HPV. En termes de revenus, ce type a dominé le marché du dépistage du cancer du col de l'utérus en 2021, et il devrait continuer à dominer au cours de la période de prévision.
Aperçus stratégiques
Régions lucratives pour le cancer du col de l'utérus Marché des tests de diagnostic
Aperçus du marchéAugmentation de la prévalence du cancer pour stimuler la croissance du marché des tests de diagnostic du cancer du col de l'utérus au cours de la période de prévision
Le cancer est devenu l'une des principales causes de décès dans le monde. Selon l'Organisation mondiale de la santé (OMS), le cancer était la première cause de décès chez les personnes de moins de 70 ans dans 183 pays et la quatrième cause de décès dans 123 pays dans le monde en 2019. De plus, selon les données publiées par le OMS en mars 2021, environ 10 millions de décès sont survenus en 2020 en raison de différents types de cancer. L'incidence croissante du cancer du col de l'utérus chez les femmes dans le monde stimule la croissance du marché des tests de diagnostic du cancer du col de l'utérus. Selon l'OMS, plus de 270 000 décès de femmes sont enregistrés chaque année à cause du cancer du col de l'utérus. Les taux de mortalité par cancer du col de l'utérus sont plus élevés dans les pays à faible revenu en raison du diagnostic tardif de la maladie. Le marché devrait croître dans les années à venir en raison de l'acceptation croissante des tests de diagnostic du cancer du col de l'utérus pour la détection précoce de la maladie. La prévalence croissante du cancer a créé un fardeau pour les systèmes de santé à travers le monde. Selon le Centre international de recherche sur le cancer (CIRC), le fardeau mondial des nouveaux cas de cancer devrait atteindre environ 27,5 millions d'ici 2040, et la maladie devrait être la cause d'environ 163 millions de décès cette année-là. Des facteurs tels que les changements de mode de vie, le tabagisme, la réduction des activités physiques et les conditions sanitaires et climatiques incertaines conduiraient à un fardeau encore plus lourd du cancer dans le monde dans les années à venir.
Insights basés sur les types
En fonction du type, le marché des tests de diagnostic du cancer du col de l'utérus est segmenté en tests PAP, tests HPV, colposcopie, biopsies cervicales, cystoscopie et autres. En 2021, le segment des tests PAP détenait la plus grande part du marché, et on estime qu'il enregistrera le TCAC le plus élevé entre 2021 et 2028.
Marché des tests de diagnostic du cancer du col de l'utérus, par type - 2021 et 2028 Informations basées sur le fournisseur de services
En fonction du fournisseur de services, le marché est segmenté en laboratoires de recherche, de diagnostic et de recherche, hôpitaux et cliniques, cliniques spécialisées et services de soins à domicile. En 2021, le segment des laboratoires de diagnostic et de recherche détenait la plus grande part du marché et devrait enregistrer le TCAC le plus élevé du marché au cours de la période 2021-2028. Les entreprises opérant sur le marché des tests de diagnostic du cancer du col utérin adoptent diverses stratégies telles que les innovations de produits. , pour répondre à l'évolution des demandes des clients à travers le monde et maintenir leur marque sur le marché mondial.
Marché des tests de diagnostic du cancer du col de l'utérus - Segmentation
Le marché des tests de diagnostic du cancer du col de l'utérus est segmenté sur la base du type et du fournisseur de services. En fonction du type, le marché est sous-segmenté en tests PAP, tests HPV, colposcopie, biopsies cervicales, cystoscopie et autres. En fonction du fournisseur de services, le marché est en outre segmenté en laboratoires de diagnostic et de recherche, hôpitaux et cliniques, cliniques spécialisées et services de soins à domicile. En termes géographiques, le marché des tests de diagnostic du cancer du col de l'utérus est segmenté en Amérique du Nord (États-Unis, Canada et Mexique), en Europe (France, Allemagne, Italie, Royaume-Uni, Espagne et reste de l'Europe), en Asie-Pacifique (Australie, Chine, Inde, Japon, Corée du Sud et reste de l'APAC), Moyen-Orient et Afrique (Arabie saoudite, Afrique du Sud, Émirats arabes unis et reste de la MEA) et Amérique du Sud et centrale (Brésil, Argentine et reste de la SCAM ).
Profils d'entreprise
- F. Hoffmann-La Roche Ltd.
- Abbott
- Quest Diagnostics Incorporated
- QIAGEN
- Hologic, Inc.
- DYSIS Medical Inc.
- Femasys Inc.
- Guided Therapeutics, Inc.
- Cooper Companies, Inc.
- BD
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Cervical Cancer refers to cancer that occurs in the cells of the cervix i.e. the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening.
The factors that are driving and restraining factors that will affect the cervical cancer diagnostic testing market in the coming years. Factors such as the increasing prevalence of cancer and the rise in HPV infections are driving the market growth. However, less number of commercially available vaccines for the treatment of cancer are likely to hamper the growth of the market.
The cervical cancer diagnostic testing market majorly consists of the players such as as F. Hoffmann-La Roche Ltd., Abbott, Quest Diagnostics Incorporated, QIAGEN, Hologic, Inc., DYSIS Medical Inc., Femasys Inc., Guided Therapeutics, Inc, Cooper Companies, Inc., BD are amongst others.
The global cervical cancer diagnostic testing market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North American area holds the largest market for aesthetic skin devices. The United States held the most significant cervical cancer diagnostic testing market and is expected to grow due to factors such as high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which have increased the reach of insurance coverage for cervical screening tests, especially for low-income women, and others.
The cervical cancer diagnostic testing market based on type is segmented into PAP testing, HPV testing, colposcopy, cervical biopsies, cystoscopy, others. In 2021, the PAP Testing segment accounted for the highest share. Besides, the HPV testing segment is expected to grow at a CAGR of 5.5% in the forecast period.
Asia Pacific is registered as the fastest-growing region in the global cervical cancer diagnostic testing market. The market is this region is expected to grow significantly in countries such as China, Japan, and India. The market is driven by the increasing prevalence of cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea, and Australia.
The List of Companies - Cervical Cancer Diagnostic Testing Market
- F. HOFFMANN-LA ROCHE LTD.
- Abbott
- Quest Diagnostics Incorporated
- QIAGEN
- Hologic, Inc.
- DYSIS Medical Inc
- Femasys Inc.
- GUIDED THERAPEUTICS, INC
- Cooper Companies, Inc.
- BD
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Dec 2021
Colonoscopes Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Fiber Optic Colonoscopy Devices, Video Colonoscopy Devices); Application (Colorectal Cancer, Lynch Syndrome, Ulcerative Colitis, Crohn's Disease, Polyp); End User (Hospitals, Ambulatory Surgery Center, Others), and Geography
Dec 2021
Noninvasive Fat Reduction Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Cryolipolysis, Laser Lipolysis, Ultrasound, and Others), End User (Hospitals, Dermatology Clinics & Cosmetic Clinics, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2021
Medical Ultrasound Flow Meter Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Implementation Type (Clamp-On, Inline, and Others), Technology (Doppler, Transit Time, and Hybrid), Application (Heart and Lung Machines, Extracorporeal Membrane Oxygenation, Perfusion, Organ Transportation Systems, and Others), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Research Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2021
Rapid Test Kits Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Rapid Antigen Testing, Rapid Antibody Testing, and Others), Product (Over-the-Counter Rapid Testing Kit and Professional Rapid Testing Kit), Technology (Lateral Flow Assay, Solid Phase, Agglutination, Immunospot Assay, and Cellular Component-Based), Application (Blood Glucose Testing, Infectious Disease Testing, Pregnancy and Fertility, Cardiometabolic Testing, and Others), End User (Hospital and Clinics, Home Care, Diagnostics Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2021
Osteoarthritis Therapy Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type [Transcutaneous Electrical Nerve Stimulation (TENS), Occupational Therapy, Physical Therapy, Platelet-Rich Plasma Therapy and Stromal Vascular Fraction, Prolotherapy, and Others], Disease Indication (Knee Osteoarthritis, Spine Osteoarthritis, Foot and Ankle Osteoarthritis, Shoulder Osteoarthritis, Hand Osteoarthritis, and Others), End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2021
Bariatric Surgeries Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type [Adjustable Gastric Bands (AGB), Sleeve Gastrectomy, Gastric Bypass, Biliopancreatic Diversion with Duodenal Switch (BPD-DS), and Others], End User (Hospitals and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2021
Post-Acute Care Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Service Type (Skilled Nursing Facilities, Inpatient Rehabilitation Facilities, Long-Term Care Hospitals, Home Health Agency, and Others), Age (Elderly, Adult, and Others), Disease Conditions (Amputations, Wound Management, Brain Injury and Spinal Cord Injury, Neurological Disorders, and Others), and Geography
Dec 2021
Lung Cancer Therapy Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)